Provided by Tiger Trade Technology Pte. Ltd.

CARSGEN-B

17.420
-0.040-0.23%
Volume:7.06M
Turnover:123.44M
Market Cap:9.93B
PE:-86.77
High:18.040
Open:17.340
Low:17.100
Close:17.460
52wk High:25.600
52wk Low:9.900
Shares:570.00M
HK Float Shares:570.00M
Volume Ratio:1.26
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.201
ROE:-11.21%
ROA:-9.61%
PB:11.19
PE(LYR):-86.77
PS:69.77

Loading ...

CARsGen-B Shares Extend Decline Amid TCE Data Impact on Autologous CAR-T Outlook

Stock News
·
Mar 02

CARsgen (2171) Schedules Board Meeting to Review 2025 Annual Results

Bulletin Express
·
Feb 24

Assessing CARsgen Therapeutics Holdings (SEHK:2171) Valuation After New CAR T-Cell Manufacturing Partnership

Simply Wall St.
·
Feb 24

Assessing CARsgen Therapeutics Holdings’ Valuation After New CAR T-Cell Manufacturing Cooperation News

Simply Wall St.
·
Feb 17

High Growth Tech Stocks In Asia With Promising Potential

Simply Wall St.
·
Feb 13

CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai

THOMSON REUTERS
·
Feb 13

CARSGEN-B Forges Strategic Partnership to Establish Commercial CAR-T Production Facility in Shanghai

Stock News
·
Feb 13

BRIEF-CARsgen Therapeutics Entering Into Strategic Cooperation Agreements

Reuters
·
Feb 13

CARsgen Therapeutics Invests Up to RMB370 Million in Shanghai CAR T-Cell Manufacturing Base

Reuters
·
Feb 13

CARsgen Therapeutics - Investment of RMB370 Mln for Manufacturing Base in Shanghai

THOMSON REUTERS
·
Feb 13

CARsgen Therapeutics Holdings Ltd - Entering Into Strategic Cooperation Agreements

THOMSON REUTERS
·
Feb 13

CARsgen Therapeutics - Co Will Establish Advanced Commercial Manufacturing Base for Car T-Cell Products in Jinshan District, Shanghai

THOMSON REUTERS
·
Feb 13

BRIEF-Carsgen Therapeutics Sees FY Net Loss Of Up To RMB120 MLN

Reuters
·
Jan 26

CARsgen Therapeutics Forecasts Narrower 2025 Losses

MT Newswires Live
·
Jan 26

CARSGEN-B (02171) Issues Profit Warning, Anticipates 2025 Net Loss to Narrow to No More Than Approximately RMB 120 Million

Stock News
·
Jan 26

CARsgen Therapeutics - Net Loss Expected to Reduce to up to RMB120 Mln in FY

THOMSON REUTERS
·
Jan 26

CARsgen Therapeutics - Loss Reduction Due to Increased Revenues From Zevorcabtagene Autoleucel, Others in FY

THOMSON REUTERS
·
Jan 26

CARsgen Therapeutics forecasts sharp reduction in annual net loss for 2025

Reuters
·
Jan 26

CARsgen Therapeutics files HKEX disclosure for 245,000-share repurchase at HKD16.52 each

Reuters
·
Jan 26

How CARsgen’s Solid Tumor CAR T Virus Combo Trial Could Reshape Its Story for Investors (SEHK:2171)

Simply Wall St.
·
Jan 25